Published 2021 | Version v1
Publication Metadata-only

Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': (ESMO Open (2021) 6(2), (S2059702921000089), (10.1016/j.esmoop.2021.100054))

De Angelis C.
Bruzzese D.
Bernardo A.
Baldini E.
Leo L.
Fabi A.
Gamucci T.
De Placido P.
Poggio F.
Russo S.
Forestieri V.
Lauria R.
De Santo I.
Caputo R.
Cianniello D.
Michelotti A.
Del Mastro L.
De Laurentiis M.
Giuliano M.
De Placido S.
Arpino G.
Others:
De Angelis, C.
Bruzzese, D.
Bernardo, A.
Baldini, E.
Leo, L.
Fabi, A.
Gamucci, T.
De Placido, P.
Poggio, F.
Russo, S.
Forestieri, V.
Lauria, R.
De Santo, I.
Caputo, R.
Cianniello, D.
Michelotti, A.
Del Mastro, L.
De Laurentiis, M.
Giuliano, M.
De Placido, S.
Arpino, G.

Description

The authors regret that at the time the article was published the following two authors were missing from the author list: R. Caputo and D. Cianniello. Both authors affiliation is the Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy. The updated author list is as follows: C. De Angelis, D. Bruzzese, A. Bernardo, E. Baldini, L. Leo, A. Fabi, T. Gamucci, P. De Placido, F. Poggio, S. Russo, V. Forestieri, R. Lauria, I. De Santo, R. Caputo, D. Cianniello, A. Michelotti, L. Del Mastro, M. De Laurentiis, M. Giuliano, S. De Placido, G. Arpino. The authors would like to apologise for any inconvenience caused.

Additional details

Identifiers Origin repository
Created:
February 14, 2024
Modified:
February 14, 2024